Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space

HC Wainwright initiated coverage on LAVA Therapeutics NV LVTX with a Buy rating and a price target of $9.
The company is focused on developing Gammabodies for cancer treatments.
According to the analyst, the Gammabody platform could deliver superior anti-tumor activity by leveraging γδ T cells' advantages, such as broad antigen recognition, distinguishing healthy tissues from the tumor, and activating proinflammatory immune systems cascades.
The lead candidate, LAVA-051, is being evaluated in a Phase 1/2a study in multiple blood cancer settings.
Initial Phase 1 data showed a favorable safety profile and early signs of clinical activity.
Additional dose-escalation data is expected in 2H22, and initial Phase 2a data from the expansion cohorts in 1H23.
Related: LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen.
LAVA is also evaluating LAVA-1207 in a Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) therapy, with initial data expected in 4Q22/1Q23.
"We believe Gammabody could be a game changer in the bispecific T cell engagers space. We currently project LAVA to generate risk-adjusted peak revenues of $391 million in 2032, growing from $4 million in 2026," the analyst writes.
Price Action: LVTX shares are down 0.20% at $4.25 on the last check Tuesday.

Analyst Calendar